PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
35062878-4	2022	UGT2B10 is a phase II drug metabolizing enzyme involved in the N-glucuronidation of tertiary amine containing drugs.	Nitrogen	63-64	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	0-7
12639971-6	2003	Interestingly, UGT2B10 and UGT2B11, which are considered as orphan enzymes since no conjugation activity has so far been demonstrated with these enzymes, conjugated 12-HETE, 15-HETE, and 13-HODE.	12-Hete	165-172	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	15-22
12639971-6	2003	Interestingly, UGT2B10 and UGT2B11, which are considered as orphan enzymes since no conjugation activity has so far been demonstrated with these enzymes, conjugated 12-HETE, 15-HETE, and 13-HODE.	5-hydroxy-6,8,11,14-eicosatetraenoic acid	168-172	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	15-22
12639971-6	2003	Interestingly, UGT2B10 and UGT2B11, which are considered as orphan enzymes since no conjugation activity has so far been demonstrated with these enzymes, conjugated 12-HETE, 15-HETE, and 13-HODE.	13-hydroxy-9,11-octadecadienoic acid	190-194	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	15-22
8674824-4	1995	Among these UGTs, UGT2B7 is specific for estriol and 3,4-catechol estrogens, UGT2B15 glucuronidates 17beta-hydroxy-C19 steroids while UGT2B10 has as yet an undescribed activity.	Estriol	41-48	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	134-141
8269638-1	1993	The capacity of four cDNA-expressed human liver UDP-glucuronosyltransferases (UGT), UGT1*6, UGT2B7, UGT2B10 and UGT2B11, to glucuronidate hydroxylated metabolites of benzo[a]pyrene (B[a]P) and 2-acetylaminofluorene (AAF) has been investigated.	glucuronidate	124-137	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	100-107
8269638-1	1993	The capacity of four cDNA-expressed human liver UDP-glucuronosyltransferases (UGT), UGT1*6, UGT2B7, UGT2B10 and UGT2B11, to glucuronidate hydroxylated metabolites of benzo[a]pyrene (B[a]P) and 2-acetylaminofluorene (AAF) has been investigated.	Benzo(a)pyrene	166-180	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	100-107
8269638-1	1993	The capacity of four cDNA-expressed human liver UDP-glucuronosyltransferases (UGT), UGT1*6, UGT2B7, UGT2B10 and UGT2B11, to glucuronidate hydroxylated metabolites of benzo[a]pyrene (B[a]P) and 2-acetylaminofluorene (AAF) has been investigated.	2-Acetylaminofluorene	193-214	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	100-107
8269638-1	1993	The capacity of four cDNA-expressed human liver UDP-glucuronosyltransferases (UGT), UGT1*6, UGT2B7, UGT2B10 and UGT2B11, to glucuronidate hydroxylated metabolites of benzo[a]pyrene (B[a]P) and 2-acetylaminofluorene (AAF) has been investigated.	2-Acetylaminofluorene	216-219	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	100-107
35062878-4	2022	UGT2B10 is a phase II drug metabolizing enzyme involved in the N-glucuronidation of tertiary amine containing drugs.	tertiary amine	84-98	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	0-7
35062878-10	2022	RESULTS: Four potential ligands for UGT2B10 namely acetaminophen, lorazepam, mycophenolic acid and voriconazole n-oxide intermediate were identified.	Acetaminophen	51-64	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	36-43
35062878-10	2022	RESULTS: Four potential ligands for UGT2B10 namely acetaminophen, lorazepam, mycophenolic acid and voriconazole n-oxide intermediate were identified.	Lorazepam	66-75	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	36-43
35062878-10	2022	RESULTS: Four potential ligands for UGT2B10 namely acetaminophen, lorazepam, mycophenolic acid and voriconazole n-oxide intermediate were identified.	Mycophenolic Acid	77-94	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	36-43
35062878-10	2022	RESULTS: Four potential ligands for UGT2B10 namely acetaminophen, lorazepam, mycophenolic acid and voriconazole n-oxide intermediate were identified.	Voriconazole N-Oxide	99-119	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	36-43
35062878-11	2022	Other metabolites of voriconazole satisfied the criteria of being possible ligands of UGT2B10.	Voriconazole	21-33	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	86-93
31699808-4	2020	Where cytochrome P450 (P450) was responsible for the metabolism in rats with a low Michaelis constant, human-specific UDP-glucuronosyltransferase 2B10- and 1A4-mediated N-glucuronidation was identified as the leading contributor to metabolism in humans with a high V max capacity.	Nitrogen	169-170	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	118-159
33741369-4	2021	Following screening a variety of phenolic compound(s), we have found that methylophiopogonanone A (MOA) can be readily O-glucuronidated by all tested human UGTs, including the typical N-glucuronidating enzymes UGT1A4 and UGT2B10.	methylophiopogonanone	74-95	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	221-228
31839590-7	2020	Of these, dothiepin, cidoxepin, cyclobenzaprine, azatadine, cyproheptadine, bifonazole, and asenapine were indicated to be selective UGT2B10 substrates which have not previously been described.	Dothiepin	10-19	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	133-140
31839590-7	2020	Of these, dothiepin, cidoxepin, cyclobenzaprine, azatadine, cyproheptadine, bifonazole, and asenapine were indicated to be selective UGT2B10 substrates which have not previously been described.	doxepin	21-30	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	133-140
31839590-7	2020	Of these, dothiepin, cidoxepin, cyclobenzaprine, azatadine, cyproheptadine, bifonazole, and asenapine were indicated to be selective UGT2B10 substrates which have not previously been described.	cyclobenzaprine	32-47	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	133-140
31839590-7	2020	Of these, dothiepin, cidoxepin, cyclobenzaprine, azatadine, cyproheptadine, bifonazole, and asenapine were indicated to be selective UGT2B10 substrates which have not previously been described.	azatadine	49-58	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	133-140
31839590-7	2020	Of these, dothiepin, cidoxepin, cyclobenzaprine, azatadine, cyproheptadine, bifonazole, and asenapine were indicated to be selective UGT2B10 substrates which have not previously been described.	Cyproheptadine	60-74	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	133-140
31839590-7	2020	Of these, dothiepin, cidoxepin, cyclobenzaprine, azatadine, cyproheptadine, bifonazole, and asenapine were indicated to be selective UGT2B10 substrates which have not previously been described.	bifonazole	76-86	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	133-140
31839590-7	2020	Of these, dothiepin, cidoxepin, cyclobenzaprine, azatadine, cyproheptadine, bifonazole, and asenapine were indicated to be selective UGT2B10 substrates which have not previously been described.	asenapine	92-101	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	133-140
33387482-3	2021	Treatment of HepaRG cells with 3-deazaadenosine, an inhibitor of RNA methylation, significantly increased UGT1A1, UGT1A3, UGT1A4, UGT1A9, UGT2B7, UGT2B10, and UGT2B15 mRNA levels (1.3- to 2.6-fold).	3-deazaadenosine	31-47	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	146-153
29438977-1	2018	The detoxification enzyme UDP-glucuronosyltransferase UGT2B10 is specialized in the N-linked glucuronidation of many drugs and xenobiotics.	Nitrogen	84-85	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	54-61
31554697-0	2019	Potential Regulation of UGT2B10 and UGT2B7 by miR-485-5p in Human Liver.	mir-485-5p	46-56	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
31554697-9	2019	UGT2B10 and UGT2B7 activities were probed using nicotine and 3"-azido-3"-deoxythymidine, respectively, and significant decreases in glucuronidation activity were observed for both substrates in HuH-7 and Hep3B cells upon overexpression of miR-485-5p mimic.	Nicotine	48-56	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	0-7
31554697-9	2019	UGT2B10 and UGT2B7 activities were probed using nicotine and 3"-azido-3"-deoxythymidine, respectively, and significant decreases in glucuronidation activity were observed for both substrates in HuH-7 and Hep3B cells upon overexpression of miR-485-5p mimic.	Zidovudine	61-87	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	0-7
30049229-0	2018	Highly selective N-glucuronidation of four piperazine-containing drugs by UDP-glucuronosyltransferase 2B10.	Nitrogen	17-18	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	74-106
30049229-0	2018	Highly selective N-glucuronidation of four piperazine-containing drugs by UDP-glucuronosyltransferase 2B10.	Piperazine	43-53	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	74-106
30049229-5	2018	Reaction phenotyping, chemical inhibition, and activity correlation analysis revealed that UGT2B10 was a high-affinity enzyme and mainly responsible for hepatic N-glucuronidation of all drugs except mianserin.	Nitrogen	161-162	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	91-98
30049229-5	2018	Reaction phenotyping, chemical inhibition, and activity correlation analysis revealed that UGT2B10 was a high-affinity enzyme and mainly responsible for hepatic N-glucuronidation of all drugs except mianserin.	Mianserin	199-208	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	91-98
30049229-6	2018	Both UGT1A4 and UGT2B10 were important contributors to mianserin N-glucuronidation.	mianserin n	55-66	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	16-23
30049229-9	2018	CONCLUSIONS: UGT2B10 plays a critical role in N-glucuronidation of piperazine-containing drugs.	Nitrogen	2-3	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	13-20
30049229-9	2018	CONCLUSIONS: UGT2B10 plays a critical role in N-glucuronidation of piperazine-containing drugs.	Piperazine	67-77	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	13-20
29691239-0	2018	Disposition of Mianserin and Cyclizine in UGT2B10-Overexpressing Human Embryonic Kidney 293 Cells: Identification of UGT2B10 as a Novel N-Glucosidation Enzyme and Breast Cancer Resistance Protein as an N-Glucoside Transporter.	Mianserin	15-24	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	42-49
29691239-0	2018	Disposition of Mianserin and Cyclizine in UGT2B10-Overexpressing Human Embryonic Kidney 293 Cells: Identification of UGT2B10 as a Novel N-Glucosidation Enzyme and Breast Cancer Resistance Protein as an N-Glucoside Transporter.	Mianserin	15-24	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	117-124
29691239-0	2018	Disposition of Mianserin and Cyclizine in UGT2B10-Overexpressing Human Embryonic Kidney 293 Cells: Identification of UGT2B10 as a Novel N-Glucosidation Enzyme and Breast Cancer Resistance Protein as an N-Glucoside Transporter.	Cyclizine	29-38	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	117-124
29691239-2	2018	We aimed to investigate a potential role of UGT2B10 in N-glucosidation and to determine the transporters for the excretion of N-glucosides.	Nitrogen	55-56	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	44-51
29691239-10	2018	In conclusion, UGT2B10 was for the first time identified as an N-glucosidation enzyme.	Nitrogen	63-64	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	15-22
29431853-1	2018	UGT2B10 is an important metabolism enzyme in human body and its substrates include multiple amine-containing compounds, especially nicotine, tamoxifen and multiple antidepressants.	Amines	92-97	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	0-7
29431853-1	2018	UGT2B10 is an important metabolism enzyme in human body and its substrates include multiple amine-containing compounds, especially nicotine, tamoxifen and multiple antidepressants.	Nicotine	131-139	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	0-7
29431853-1	2018	UGT2B10 is an important metabolism enzyme in human body and its substrates include multiple amine-containing compounds, especially nicotine, tamoxifen and multiple antidepressants.	Tamoxifen	141-150	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	0-7
33109037-2	2020	CYP2C8 and UGT2B10 are metabolic enzymes, which may be involved in the metabolism of desloratadine.	desloratadine	85-98	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	11-18
29631575-7	2018	RESULTS: For cotinine levels, SNPs near UGT2B10 gene achieved genome-wide significance (i.e. P < 5 x 10- 8) with top SNP rs10023464, P = 1.27 x 10- 11.	Cotinine	13-21	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	40-47
29158210-8	2018	The UGT2B10 phenotype ratio (nicotine glucuronide/nicotine) was higher at early and late pregnancy compared with postpartum (P = 0.07 and P < 0.05, respectively) and correlated with a second UGT2B10 phenotype ratio (cotinine glucuronide/cotinine) (all P < 0.001), suggesting UGT2B10 activity is induced during pregnancy.	nicotine N-glucuronide	29-49	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	4-11
29158210-8	2018	The UGT2B10 phenotype ratio (nicotine glucuronide/nicotine) was higher at early and late pregnancy compared with postpartum (P = 0.07 and P < 0.05, respectively) and correlated with a second UGT2B10 phenotype ratio (cotinine glucuronide/cotinine) (all P < 0.001), suggesting UGT2B10 activity is induced during pregnancy.	Cotinine	219-227	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	4-11
29158210-8	2018	The UGT2B10 phenotype ratio (nicotine glucuronide/nicotine) was higher at early and late pregnancy compared with postpartum (P = 0.07 and P < 0.05, respectively) and correlated with a second UGT2B10 phenotype ratio (cotinine glucuronide/cotinine) (all P < 0.001), suggesting UGT2B10 activity is induced during pregnancy.	nicotine N-glucuronide	29-49	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	194-201
29158210-8	2018	The UGT2B10 phenotype ratio (nicotine glucuronide/nicotine) was higher at early and late pregnancy compared with postpartum (P = 0.07 and P < 0.05, respectively) and correlated with a second UGT2B10 phenotype ratio (cotinine glucuronide/cotinine) (all P < 0.001), suggesting UGT2B10 activity is induced during pregnancy.	nicotine N-glucuronide	29-49	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	194-201
29158210-9	2018	In conclusion, pregnancy-induced increases in nicotine metabolism start by 12 weeks gestation and continue as pregnancy progresses most likely due to induction of CYP2A6 and UGT2B10, resulting in potential reductions in the effectiveness of nicotine replacement therapies and an increase in metabolism of other CYP2A6 and UGT2B10 substrates during pregnancy.	Nicotine	46-54	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	174-181
29158210-9	2018	In conclusion, pregnancy-induced increases in nicotine metabolism start by 12 weeks gestation and continue as pregnancy progresses most likely due to induction of CYP2A6 and UGT2B10, resulting in potential reductions in the effectiveness of nicotine replacement therapies and an increase in metabolism of other CYP2A6 and UGT2B10 substrates during pregnancy.	Nicotine	46-54	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	322-329
29158210-8	2018	The UGT2B10 phenotype ratio (nicotine glucuronide/nicotine) was higher at early and late pregnancy compared with postpartum (P = 0.07 and P < 0.05, respectively) and correlated with a second UGT2B10 phenotype ratio (cotinine glucuronide/cotinine) (all P < 0.001), suggesting UGT2B10 activity is induced during pregnancy.	Nicotine	29-37	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	4-11
29158210-9	2018	In conclusion, pregnancy-induced increases in nicotine metabolism start by 12 weeks gestation and continue as pregnancy progresses most likely due to induction of CYP2A6 and UGT2B10, resulting in potential reductions in the effectiveness of nicotine replacement therapies and an increase in metabolism of other CYP2A6 and UGT2B10 substrates during pregnancy.	Nicotine	241-249	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	174-181
29158210-8	2018	The UGT2B10 phenotype ratio (nicotine glucuronide/nicotine) was higher at early and late pregnancy compared with postpartum (P = 0.07 and P < 0.05, respectively) and correlated with a second UGT2B10 phenotype ratio (cotinine glucuronide/cotinine) (all P < 0.001), suggesting UGT2B10 activity is induced during pregnancy.	Nicotine	29-37	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	194-201
29158210-8	2018	The UGT2B10 phenotype ratio (nicotine glucuronide/nicotine) was higher at early and late pregnancy compared with postpartum (P = 0.07 and P < 0.05, respectively) and correlated with a second UGT2B10 phenotype ratio (cotinine glucuronide/cotinine) (all P < 0.001), suggesting UGT2B10 activity is induced during pregnancy.	Nicotine	29-37	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	194-201
29158210-8	2018	The UGT2B10 phenotype ratio (nicotine glucuronide/nicotine) was higher at early and late pregnancy compared with postpartum (P = 0.07 and P < 0.05, respectively) and correlated with a second UGT2B10 phenotype ratio (cotinine glucuronide/cotinine) (all P < 0.001), suggesting UGT2B10 activity is induced during pregnancy.	cotinine N-glucuronide	219-239	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	4-11
28803208-6	2017	In addition, UGT1A4 and UGT2B10 were primarily responsible for N-glucuronidation of many tertiary amines, including asenapine, loxapine, clozapine, chlorpromazine, dothiepin, doxepin, mirtazapine, mianserin, chlorcyclizine, cyclizine, promethazine, cyclobenzaprine, imatinib, retrorsine, strychnine and brucine.	Nitrogen	63-64	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
28803208-6	2017	In addition, UGT1A4 and UGT2B10 were primarily responsible for N-glucuronidation of many tertiary amines, including asenapine, loxapine, clozapine, chlorpromazine, dothiepin, doxepin, mirtazapine, mianserin, chlorcyclizine, cyclizine, promethazine, cyclobenzaprine, imatinib, retrorsine, strychnine and brucine.	Amines	98-104	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
28803208-0	2017	N-glucuronidation catalyzed by UGT1A4 and UGT2B10 in human liver microsomes: Assay optimization and substrate identification.	Nitrogen	0-1	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	42-49
28803208-3	2017	However, the metabolic patterns of UGT1A4- and UGT2B10-mediated N-glucuronidation are not fully clear.	Nitrogen	64-65	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	47-54
28803208-4	2017	In this study, we first optimized in vitro reaction conditions for N-glucuronidation by using specific substrates (i.e., trifluoperazine for UGT1A4, cotinine and amitriptyline for UGT2B10).	Nitrogen	67-68	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	180-187
28803208-4	2017	In this study, we first optimized in vitro reaction conditions for N-glucuronidation by using specific substrates (i.e., trifluoperazine for UGT1A4, cotinine and amitriptyline for UGT2B10).	Trifluoperazine	121-136	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	180-187
28803208-4	2017	In this study, we first optimized in vitro reaction conditions for N-glucuronidation by using specific substrates (i.e., trifluoperazine for UGT1A4, cotinine and amitriptyline for UGT2B10).	Amitriptyline	162-175	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	180-187
28803208-6	2017	In addition, UGT1A4 and UGT2B10 were primarily responsible for N-glucuronidation of many tertiary amines, including asenapine, loxapine, clozapine, chlorpromazine, dothiepin, doxepin, mirtazapine, mianserin, chlorcyclizine, cyclizine, promethazine, cyclobenzaprine, imatinib, retrorsine, strychnine and brucine.	asenapine	116-125	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
28803208-6	2017	In addition, UGT1A4 and UGT2B10 were primarily responsible for N-glucuronidation of many tertiary amines, including asenapine, loxapine, clozapine, chlorpromazine, dothiepin, doxepin, mirtazapine, mianserin, chlorcyclizine, cyclizine, promethazine, cyclobenzaprine, imatinib, retrorsine, strychnine and brucine.	Loxapine	127-135	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
28803208-6	2017	In addition, UGT1A4 and UGT2B10 were primarily responsible for N-glucuronidation of many tertiary amines, including asenapine, loxapine, clozapine, chlorpromazine, dothiepin, doxepin, mirtazapine, mianserin, chlorcyclizine, cyclizine, promethazine, cyclobenzaprine, imatinib, retrorsine, strychnine and brucine.	Clozapine	137-146	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
28803208-6	2017	In addition, UGT1A4 and UGT2B10 were primarily responsible for N-glucuronidation of many tertiary amines, including asenapine, loxapine, clozapine, chlorpromazine, dothiepin, doxepin, mirtazapine, mianserin, chlorcyclizine, cyclizine, promethazine, cyclobenzaprine, imatinib, retrorsine, strychnine and brucine.	Chlorpromazine	148-162	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
28803208-6	2017	In addition, UGT1A4 and UGT2B10 were primarily responsible for N-glucuronidation of many tertiary amines, including asenapine, loxapine, clozapine, chlorpromazine, dothiepin, doxepin, mirtazapine, mianserin, chlorcyclizine, cyclizine, promethazine, cyclobenzaprine, imatinib, retrorsine, strychnine and brucine.	Dothiepin	164-173	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
28803208-6	2017	In addition, UGT1A4 and UGT2B10 were primarily responsible for N-glucuronidation of many tertiary amines, including asenapine, loxapine, clozapine, chlorpromazine, dothiepin, doxepin, mirtazapine, mianserin, chlorcyclizine, cyclizine, promethazine, cyclobenzaprine, imatinib, retrorsine, strychnine and brucine.	Doxepin	175-182	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
28803208-6	2017	In addition, UGT1A4 and UGT2B10 were primarily responsible for N-glucuronidation of many tertiary amines, including asenapine, loxapine, clozapine, chlorpromazine, dothiepin, doxepin, mirtazapine, mianserin, chlorcyclizine, cyclizine, promethazine, cyclobenzaprine, imatinib, retrorsine, strychnine and brucine.	Mirtazapine	184-195	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
28803208-6	2017	In addition, UGT1A4 and UGT2B10 were primarily responsible for N-glucuronidation of many tertiary amines, including asenapine, loxapine, clozapine, chlorpromazine, dothiepin, doxepin, mirtazapine, mianserin, chlorcyclizine, cyclizine, promethazine, cyclobenzaprine, imatinib, retrorsine, strychnine and brucine.	Mianserin	197-206	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
28803208-6	2017	In addition, UGT1A4 and UGT2B10 were primarily responsible for N-glucuronidation of many tertiary amines, including asenapine, loxapine, clozapine, chlorpromazine, dothiepin, doxepin, mirtazapine, mianserin, chlorcyclizine, cyclizine, promethazine, cyclobenzaprine, imatinib, retrorsine, strychnine and brucine.	chlorcyclizine	208-222	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
28803208-6	2017	In addition, UGT1A4 and UGT2B10 were primarily responsible for N-glucuronidation of many tertiary amines, including asenapine, loxapine, clozapine, chlorpromazine, dothiepin, doxepin, mirtazapine, mianserin, chlorcyclizine, cyclizine, promethazine, cyclobenzaprine, imatinib, retrorsine, strychnine and brucine.	Cyclizine	213-222	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
28803208-6	2017	In addition, UGT1A4 and UGT2B10 were primarily responsible for N-glucuronidation of many tertiary amines, including asenapine, loxapine, clozapine, chlorpromazine, dothiepin, doxepin, mirtazapine, mianserin, chlorcyclizine, cyclizine, promethazine, cyclobenzaprine, imatinib, retrorsine, strychnine and brucine.	Promethazine	235-247	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
28803208-6	2017	In addition, UGT1A4 and UGT2B10 were primarily responsible for N-glucuronidation of many tertiary amines, including asenapine, loxapine, clozapine, chlorpromazine, dothiepin, doxepin, mirtazapine, mianserin, chlorcyclizine, cyclizine, promethazine, cyclobenzaprine, imatinib, retrorsine, strychnine and brucine.	cyclobenzaprine	249-264	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
28803208-6	2017	In addition, UGT1A4 and UGT2B10 were primarily responsible for N-glucuronidation of many tertiary amines, including asenapine, loxapine, clozapine, chlorpromazine, dothiepin, doxepin, mirtazapine, mianserin, chlorcyclizine, cyclizine, promethazine, cyclobenzaprine, imatinib, retrorsine, strychnine and brucine.	Imatinib Mesylate	266-274	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
28803208-6	2017	In addition, UGT1A4 and UGT2B10 were primarily responsible for N-glucuronidation of many tertiary amines, including asenapine, loxapine, clozapine, chlorpromazine, dothiepin, doxepin, mirtazapine, mianserin, chlorcyclizine, cyclizine, promethazine, cyclobenzaprine, imatinib, retrorsine, strychnine and brucine.	retrorsine	276-286	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
28803208-6	2017	In addition, UGT1A4 and UGT2B10 were primarily responsible for N-glucuronidation of many tertiary amines, including asenapine, loxapine, clozapine, chlorpromazine, dothiepin, doxepin, mirtazapine, mianserin, chlorcyclizine, cyclizine, promethazine, cyclobenzaprine, imatinib, retrorsine, strychnine and brucine.	Strychnine	288-298	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
28803208-6	2017	In addition, UGT1A4 and UGT2B10 were primarily responsible for N-glucuronidation of many tertiary amines, including asenapine, loxapine, clozapine, chlorpromazine, dothiepin, doxepin, mirtazapine, mianserin, chlorcyclizine, cyclizine, promethazine, cyclobenzaprine, imatinib, retrorsine, strychnine and brucine.	brucine	303-310	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
28803208-8	2017	Also, UGT1A4- and UGT2B10-mediated N-glucuronidation might play significant roles in metabolism and detoxification of tertiary amines in humans.	Nitrogen	35-36	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	18-25
28803208-8	2017	Also, UGT1A4- and UGT2B10-mediated N-glucuronidation might play significant roles in metabolism and detoxification of tertiary amines in humans.	tertiary amines	118-133	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	18-25
25503386-9	2015	Our results highlight the need to include UGT2B10 when screening the human UGTs for the enzymes involved in the glucuronidation of a new compound, particularly when there is a possibility of N-glucuronidation.	Nitrogen	191-192	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	42-49
28267333-1	2017	Little is known about transcriptional regulators of UDP-glucuronosyltransferase 2B10 (UGT2B10), an enzyme known to glucuronidate many chemicals and drugs such as nicotine and tricyclic antidepressants.	Nicotine	162-170	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	52-84
28267333-1	2017	Little is known about transcriptional regulators of UDP-glucuronosyltransferase 2B10 (UGT2B10), an enzyme known to glucuronidate many chemicals and drugs such as nicotine and tricyclic antidepressants.	Nicotine	162-170	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	86-93
28267333-2	2017	Here, we uncovered that UGT2B10 was transcriptionally regulated by farnesoid X receptor (FXR), the bile acid sensing nuclear receptor.	Bile Acids and Salts	99-108	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
28267333-3	2017	GW4064 and chenodeoxycholic acid (two specific FXR agonists) treatment of HepG2 cells led to a significant increase in the mRNA level of UGT2B10.	GW 4064	0-6	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	137-144
28267333-3	2017	GW4064 and chenodeoxycholic acid (two specific FXR agonists) treatment of HepG2 cells led to a significant increase in the mRNA level of UGT2B10.	Chenodeoxycholic Acid	11-32	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	137-144
28267333-4	2017	The treated cells also showed enhanced glucuronidation activities toward amitriptyline (an UGT2B10 probe substrate).	Amitriptyline	73-86	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	91-98
26669329-1	2016	Although there is evidence for an important role of UGT2B10 in the N-glucuronidation of drugs and other xenobiotics, the inhibitor selectivity of this enzyme is poorly understood.	Nitrogen	67-68	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	52-59
26669329-2	2016	This study sought primarily to characterize the inhibition selectivity of UGT2B10 by UDP-glucuronosyltransferase (UGT) enzyme-selective inhibitors used for reaction phenotyping, and 34 antidepressant and antipsychotic drugs that contain an amine functional group.	Amines	240-245	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	74-81
26669329-3	2016	Initial studies demonstrated that cotinine is a highly selective substrate of human liver microsomal UGT2B10.	Cotinine	34-42	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	101-108
26669329-5	2016	Of the UGT enzyme-selective inhibitors employed for reaction phenotyping, only the UGT2B4/7 inhibitor fluconazole reduced recombinant UGT2B10 activity to an appreciable extent.	Fluconazole	102-113	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	134-141
26669329-10	2016	values for amitriptyline, doxepin, and mianserin inhibition of human liver microsomal UGT2B10 were 0.61 +- 0.05, 0.95 +- 0.18, and 0.43 +- 0.01 microM.	Amitriptyline	11-24	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	86-93
26669329-10	2016	values for amitriptyline, doxepin, and mianserin inhibition of human liver microsomal UGT2B10 were 0.61 +- 0.05, 0.95 +- 0.18, and 0.43 +- 0.01 microM.	Doxepin	26-33	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	86-93
26669329-10	2016	values for amitriptyline, doxepin, and mianserin inhibition of human liver microsomal UGT2B10 were 0.61 +- 0.05, 0.95 +- 0.18, and 0.43 +- 0.01 microM.	Mianserin	39-48	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	86-93
26833182-5	2016	This variant is in high linkage disequilibrium with a known functional variant in the UGT2B10 gene which is associated with reduced nicotine and cotinine glucuronidation activity, but intriguingly is not associated with nicotine intake.	Nicotine	132-140	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	86-93
26833182-5	2016	This variant is in high linkage disequilibrium with a known functional variant in the UGT2B10 gene which is associated with reduced nicotine and cotinine glucuronidation activity, but intriguingly is not associated with nicotine intake.	Cotinine	145-153	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	86-93
25595597-0	2015	A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement.	3-hydroxydesloratadine	49-71	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	141-173
25595597-0	2015	A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement.	desloratadine	58-71	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	141-173
27474751-8	2016	UGT2B4 activity against codeine and UGT2B10 activity against nicotine were significantly decreased in both HuH-7 and Hep3B cells (P < 0.001 and P = 0.0048, and P = 0.017 and P = 0.043, respectively) after overexpression of miR-216b-5p mimic.	Nicotine	61-69	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	36-43
26135009-0	2015	Further Characterization of the Metabolism of Desloratadine and Its Cytochrome P450 and UDP-glucuronosyltransferase Inhibition Potential: Identification of Desloratadine as a Relatively Selective UGT2B10 Inhibitor.	desloratadine	46-59	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	196-203
26135009-0	2015	Further Characterization of the Metabolism of Desloratadine and Its Cytochrome P450 and UDP-glucuronosyltransferase Inhibition Potential: Identification of Desloratadine as a Relatively Selective UGT2B10 Inhibitor.	desloratadine	156-169	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	196-203
26135009-2	2015	Previously we reported that the formation of 3-hydroxydesloratadine, the major human metabolite of desloratadine, involves three sequential reactions, namely N-glucuronidation by UGT2B10 followed by 3-hydroxylation by CYP2C8 followed by deconjugation (rapid, nonenzymatic hydrolysis of the N-glucuronide).	3-hydroxydesloratadine	45-67	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	179-186
26135009-2	2015	Previously we reported that the formation of 3-hydroxydesloratadine, the major human metabolite of desloratadine, involves three sequential reactions, namely N-glucuronidation by UGT2B10 followed by 3-hydroxylation by CYP2C8 followed by deconjugation (rapid, nonenzymatic hydrolysis of the N-glucuronide).	desloratadine	54-67	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	179-186
26135009-2	2015	Previously we reported that the formation of 3-hydroxydesloratadine, the major human metabolite of desloratadine, involves three sequential reactions, namely N-glucuronidation by UGT2B10 followed by 3-hydroxylation by CYP2C8 followed by deconjugation (rapid, nonenzymatic hydrolysis of the N-glucuronide).	Nitrogen	158-159	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	179-186
26135009-6	2015	Assessment of UGT inhibition identified desloratadine as a potent and relatively selective competitive inhibitor of UGT2B10 (Ki value of 1.3 muM).	desloratadine	40-53	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	116-123
26135009-7	2015	Chemical inhibition of UGT enzymes in HLM demonstrated that nicotine (UGT2B10 inhibitor) but not hecogenin (UGT1A4 inhibitor) completely inhibited the conversion of desloratadine (1 microM) to 3-hydroxydesloratadine in HLM fortified with both NADPH and UDP-glucuronic acid.	Nicotine	60-68	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	70-77
26135009-7	2015	Chemical inhibition of UGT enzymes in HLM demonstrated that nicotine (UGT2B10 inhibitor) but not hecogenin (UGT1A4 inhibitor) completely inhibited the conversion of desloratadine (1 microM) to 3-hydroxydesloratadine in HLM fortified with both NADPH and UDP-glucuronic acid.	desloratadine	165-178	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	70-77
26135009-7	2015	Chemical inhibition of UGT enzymes in HLM demonstrated that nicotine (UGT2B10 inhibitor) but not hecogenin (UGT1A4 inhibitor) completely inhibited the conversion of desloratadine (1 microM) to 3-hydroxydesloratadine in HLM fortified with both NADPH and UDP-glucuronic acid.	3-hydroxydesloratadine	193-215	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	70-77
26135009-8	2015	3-Hydroxydesloratadine formation correlated well with levomedetomidine glucuronidation (UGT2B10 marker activity) with a panel of individual CHH (r(2) = 0.72).	Medetomidine	54-70	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	88-95
25595597-8	2015	Detailed mechanistic studies with sonicated or saponin-treated CHHs, human liver microsomes, and S9 fractions showed that both NADPH and UDP-glucuronic acid are required for 3-hydroxydesloratadine formation, and studies with recombinant UDP-glucuronosyltransferase (UGT) and P450 enzymes implicated the specific involvement of UGT2B10 in addition to CYP2C8.	Saponins	47-54	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	327-334
25595597-8	2015	Detailed mechanistic studies with sonicated or saponin-treated CHHs, human liver microsomes, and S9 fractions showed that both NADPH and UDP-glucuronic acid are required for 3-hydroxydesloratadine formation, and studies with recombinant UDP-glucuronosyltransferase (UGT) and P450 enzymes implicated the specific involvement of UGT2B10 in addition to CYP2C8.	NADP	127-132	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	327-334
25595597-9	2015	Overall, our results demonstrate for the first time that desloratadine glucuronidation by UGT2B10 followed by CYP2C8 oxidation and a deconjugation event are responsible for the formation of 3-hydroxydesloratadine.	desloratadine	57-70	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	90-97
25595597-9	2015	Overall, our results demonstrate for the first time that desloratadine glucuronidation by UGT2B10 followed by CYP2C8 oxidation and a deconjugation event are responsible for the formation of 3-hydroxydesloratadine.	3-hydroxydesloratadine	190-212	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	90-97
23611809-6	2013	UGT2B10 was inactive in the glucuronidation of desipramine, nortriptyline, carbamazepine, and afloqualone.	Nortriptyline	60-73	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	0-7
25233931-2	2014	We report here on the proportion of nicotine metabolism by cytochrome P450 2A6-catalyzed C-oxidation, UDP-glucuronosyl transferase 2B10 (UGT2B10)-catalyzed N-glucuronidation and flavin monooxygenase 3-catalyzed N-oxidation in five ethnic/racial groups and the role of UGT2B10 genotype on the metabolic patterns observed.	Nicotine	36-44	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	102-135
23930678-6	2013	The formation of the various olanzapine metabolites is influenced by polymorphisms in the genes coding for CYP1A2, CYP1A expression regulator AHR, UGT1A4 and UGT2B10, as well as FMO3.	Olanzapine	29-39	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	158-165
25293881-11	2015	CONCLUSIONS: Genetic variation in UGT2B10 contributes significantly to nicotine and cotinine glucuronidation but not to nicotine dose.	Nicotine	71-79	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	34-41
25293881-11	2015	CONCLUSIONS: Genetic variation in UGT2B10 contributes significantly to nicotine and cotinine glucuronidation but not to nicotine dose.	Cotinine	84-92	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	34-41
25233931-2	2014	We report here on the proportion of nicotine metabolism by cytochrome P450 2A6-catalyzed C-oxidation, UDP-glucuronosyl transferase 2B10 (UGT2B10)-catalyzed N-glucuronidation and flavin monooxygenase 3-catalyzed N-oxidation in five ethnic/racial groups and the role of UGT2B10 genotype on the metabolic patterns observed.	Nicotine	36-44	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	137-144
25233931-2	2014	We report here on the proportion of nicotine metabolism by cytochrome P450 2A6-catalyzed C-oxidation, UDP-glucuronosyl transferase 2B10 (UGT2B10)-catalyzed N-glucuronidation and flavin monooxygenase 3-catalyzed N-oxidation in five ethnic/racial groups and the role of UGT2B10 genotype on the metabolic patterns observed.	Nicotine	36-44	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	268-275
25233931-2	2014	We report here on the proportion of nicotine metabolism by cytochrome P450 2A6-catalyzed C-oxidation, UDP-glucuronosyl transferase 2B10 (UGT2B10)-catalyzed N-glucuronidation and flavin monooxygenase 3-catalyzed N-oxidation in five ethnic/racial groups and the role of UGT2B10 genotype on the metabolic patterns observed.	Nitrogen	156-157	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	102-135
25233931-2	2014	We report here on the proportion of nicotine metabolism by cytochrome P450 2A6-catalyzed C-oxidation, UDP-glucuronosyl transferase 2B10 (UGT2B10)-catalyzed N-glucuronidation and flavin monooxygenase 3-catalyzed N-oxidation in five ethnic/racial groups and the role of UGT2B10 genotype on the metabolic patterns observed.	Nitrogen	156-157	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	137-144
25233931-2	2014	We report here on the proportion of nicotine metabolism by cytochrome P450 2A6-catalyzed C-oxidation, UDP-glucuronosyl transferase 2B10 (UGT2B10)-catalyzed N-glucuronidation and flavin monooxygenase 3-catalyzed N-oxidation in five ethnic/racial groups and the role of UGT2B10 genotype on the metabolic patterns observed.	Nitrogen	156-157	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	268-275
25233931-5	2014	The relationship of UGT2B10 genotype to nicotine metabolic pathways was determined for each group; geometric means were computed and adjusted for age, sex, creatinine, and body mass index.	Nicotine	40-48	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	20-27
24192532-0	2013	The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans.	Nicotine	70-78	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	27-34
24192532-2	2013	UDP-glucuronosyltransferase-2B10 (UGT2B10) is the primary catalyst of nicotine glucuronidation.	Nicotine	70-78	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	0-32
24192532-2	2013	UDP-glucuronosyltransferase-2B10 (UGT2B10) is the primary catalyst of nicotine glucuronidation.	Nicotine	70-78	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	34-41
24192532-3	2013	MATERIALS AND METHODS: The conversion of deuterated (D2)-nicotine to D2-nicotine-glucuronide, D2-cotinine, D2-cotinine-glucuronide, and D2-trans-3"-hydroxycotinine were quantified in 188 European Americans, and the contribution of UGT2B10 genotype to variability in first-pass nicotine glucuronidation assessed, following a procedure previously applied to nicotine C-oxidation.	deuterated (d2)-nicotine	41-65	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	231-238
24192532-3	2013	MATERIALS AND METHODS: The conversion of deuterated (D2)-nicotine to D2-nicotine-glucuronide, D2-cotinine, D2-cotinine-glucuronide, and D2-trans-3"-hydroxycotinine were quantified in 188 European Americans, and the contribution of UGT2B10 genotype to variability in first-pass nicotine glucuronidation assessed, following a procedure previously applied to nicotine C-oxidation.	Nicotine	57-65	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	231-238
24192532-8	2013	CONCLUSION: CYP2A6 and UGT2B10 genotype explain 53% of the variance in oral nicotine glucuronidation in this sample.	Nicotine	76-84	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	23-30
24192532-9	2013	CYP2A6 and UGT2B10 genetic variants are also significantly associated with undeuterated (D0) nicotine glucuronidation in individuals smoking ad libitum.	Nicotine	93-101	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	11-18
23936477-3	2013	The clearance of 3HC, which affects the NMR, occurs via renal excretion and metabolism by UGT2B17, and possibly UGT2B10, to 3HC-glucuronide.	hydroxycotinine	17-20	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	112-119
23936477-3	2013	The clearance of 3HC, which affects the NMR, occurs via renal excretion and metabolism by UGT2B17, and possibly UGT2B10, to 3HC-glucuronide.	3hc-glucuronide	124-139	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	112-119
23611809-0	2013	Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4.	Nitrogen	53-54	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	6-44
23611809-1	2013	Recent observations revealed that human UDP-glucuronosyltransferase (UGT) 2B10 catalyzes N-glucuronidation of amine-containing compounds.	Nitrogen	89-90	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	40-78
23611809-1	2013	Recent observations revealed that human UDP-glucuronosyltransferase (UGT) 2B10 catalyzes N-glucuronidation of amine-containing compounds.	Amines	110-115	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	40-78
23611809-4	2013	Using recombinant UGT2B10, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole, and midazolam.	Nitrogen	58-59	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	18-25
23611809-4	2013	Using recombinant UGT2B10, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole, and midazolam.	Amitriptyline	79-92	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	18-25
23611809-6	2013	UGT2B10 was inactive in the glucuronidation of desipramine, nortriptyline, carbamazepine, and afloqualone.	Carbamazepine	75-88	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	0-7
23611809-4	2013	Using recombinant UGT2B10, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole, and midazolam.	Imipramine	94-104	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	18-25
23611809-7	2013	This group of drugs contains secondary or primary amines, and these results suggest that UGT2B10 preferably conjugates tertiary amines.	Amines	50-56	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	89-96
23611809-4	2013	Using recombinant UGT2B10, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole, and midazolam.	Ketotifen	106-115	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	18-25
23611809-4	2013	Using recombinant UGT2B10, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole, and midazolam.	Pizotyline	117-126	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	18-25
23611809-4	2013	Using recombinant UGT2B10, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole, and midazolam.	Olanzapine	128-138	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	18-25
23611809-4	2013	Using recombinant UGT2B10, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole, and midazolam.	Diphenhydramine	140-155	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	18-25
23611809-4	2013	Using recombinant UGT2B10, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole, and midazolam.	Tamoxifen	157-166	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	18-25
23611809-7	2013	This group of drugs contains secondary or primary amines, and these results suggest that UGT2B10 preferably conjugates tertiary amines.	Amines	128-134	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	89-96
23611809-4	2013	Using recombinant UGT2B10, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole, and midazolam.	Ketoconazole	168-180	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	18-25
23611809-9	2013	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.	Amitriptyline	73-86	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	61-68
23611809-4	2013	Using recombinant UGT2B10, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole, and midazolam.	Midazolam	186-195	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	18-25
23611809-9	2013	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.	Imipramine	88-98	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	61-68
23611809-9	2013	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.	Diphenhydramine	104-119	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	61-68
23611809-10	2013	These findings suggest that UGT2B10 plays a major role in the N-glucuronidation of these drugs at therapeutic concentrations.	Nitrogen	62-63	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	28-35
23611809-12	2013	In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for tertiary amines with higher affinities and clearance values than those of UGT1A4 and UGT1A3.	Amines	134-140	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	84-91
22228205-0	2012	Glucuronidation of trans-3"-hydroxycotinine by UGT2B17 and UGT2B10.	hydroxycotinine	19-43	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	59-66
22228205-7	2012	There was 91 (P<0.0001) and 39% (P<0.001) decreases in the 3HC-N-Gluc formation activities in HLM from participants with the UGT2B10 (*2/*2) and UGT2B10 (*1/*2) genotypes, respectively, compared with that of HLM from participants with the wild-type UGT2B10 (*1/*1) genotype.	3hc-n	65-70	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	131-138
22228205-7	2012	There was 91 (P<0.0001) and 39% (P<0.001) decreases in the 3HC-N-Gluc formation activities in HLM from participants with the UGT2B10 (*2/*2) and UGT2B10 (*1/*2) genotypes, respectively, compared with that of HLM from participants with the wild-type UGT2B10 (*1/*1) genotype.	3hc-n	65-70	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	151-158
22228205-7	2012	There was 91 (P<0.0001) and 39% (P<0.001) decreases in the 3HC-N-Gluc formation activities in HLM from participants with the UGT2B10 (*2/*2) and UGT2B10 (*1/*2) genotypes, respectively, compared with that of HLM from participants with the wild-type UGT2B10 (*1/*1) genotype.	3hc-n	65-70	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	151-158
23110092-8	2012	Treatment of WM3211 or metastatic melanoma cell lines with anti-cancer agents (including vemurafenib) induced expression of UGT2B7, UGT2B10 and UGT2B15 demonstrating that melanoma cells retain the ability to re-express these same three UGTs.	Vemurafenib	89-100	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	132-139
21497036-0	2011	Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition.	nicotine N-glucuronide	73-95	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	116-123
21750471-9	2011	There was a 1.9-fold (P<0.003) decrease in the formation of both isomers of the olanzapine-10-N-glucuronide, a 2.7-fold (P<0.0001) decrease in olanzapine-4"-N-glucuronide formation, and a 2.1-fold (P=0.0002) decrease in the overall olanzapine glucuronide formation in HLM with at least one UGT2B10*2 allele.	Olanzapine 10-N-glucuronide	83-110	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	296-303
21750471-9	2011	There was a 1.9-fold (P<0.003) decrease in the formation of both isomers of the olanzapine-10-N-glucuronide, a 2.7-fold (P<0.0001) decrease in olanzapine-4"-N-glucuronide formation, and a 2.1-fold (P=0.0002) decrease in the overall olanzapine glucuronide formation in HLM with at least one UGT2B10*2 allele.	Olanzapine	83-93	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	296-303
21750471-9	2011	There was a 1.9-fold (P<0.003) decrease in the formation of both isomers of the olanzapine-10-N-glucuronide, a 2.7-fold (P<0.0001) decrease in olanzapine-4"-N-glucuronide formation, and a 2.1-fold (P=0.0002) decrease in the overall olanzapine glucuronide formation in HLM with at least one UGT2B10*2 allele.	Glucuronides	99-110	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	296-303
21750471-10	2011	In regression analysis, the UGT1A4*3 (P<0.02) and UGT2B10*2 (P<0.002) alleles were significant predictors of the formation of all olanzapine glucuronide isomers.	Olanzapine 10-N-glucuronide	136-158	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	53-60
21750471-12	2011	These data suggest that the UGT1A4*3 and UGT2B10*2 alleles contribute significantly to interindividual variability in olanzapine metabolism.	Olanzapine	118-128	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	41-48
21434773-9	2011	The N-glucuronidation rates in humans are typically much higher than in animals, largely due to the activity of two enzymes, the extensively studied UGT1A4, and the more recently identified as a main player in N-glucuronidation, UGT2B10.	Nitrogen	4-5	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	229-236
21434773-9	2011	The N-glucuronidation rates in humans are typically much higher than in animals, largely due to the activity of two enzymes, the extensively studied UGT1A4, and the more recently identified as a main player in N-glucuronidation, UGT2B10.	Nitrogen	210-211	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	229-236
21434773-10	2011	We discuss both enzymes and review the findings that revealed the role of UGT2B10 in N-glucuronidation.	Nitrogen	85-86	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	74-81
21497036-1	2011	Nicotine is considered to be a specific substrate for UGT2B10, an isoform of human uridine diphosphate glucuronosyltransferase (UGT).	Nicotine	0-8	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	54-61
21497036-9	2011	This established method was employed to evaluate the inhibitory effects of five target compounds including amitriptyline, hecogenin, imipramine, lamotrigine, and trifluoperazine on enzymatic activity of UGT2B10.	Amitriptyline	107-120	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	203-210
21497036-9	2011	This established method was employed to evaluate the inhibitory effects of five target compounds including amitriptyline, hecogenin, imipramine, lamotrigine, and trifluoperazine on enzymatic activity of UGT2B10.	hecogenin	122-131	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	203-210
21497036-9	2011	This established method was employed to evaluate the inhibitory effects of five target compounds including amitriptyline, hecogenin, imipramine, lamotrigine, and trifluoperazine on enzymatic activity of UGT2B10.	Imipramine	133-143	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	203-210
21497036-9	2011	This established method was employed to evaluate the inhibitory effects of five target compounds including amitriptyline, hecogenin, imipramine, lamotrigine, and trifluoperazine on enzymatic activity of UGT2B10.	Lamotrigine	145-156	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	203-210
21497036-9	2011	This established method was employed to evaluate the inhibitory effects of five target compounds including amitriptyline, hecogenin, imipramine, lamotrigine, and trifluoperazine on enzymatic activity of UGT2B10.	Trifluoperazine	162-177	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	203-210
21497036-11	2011	Trifluoperazine was found to be a non-substrate inhibitor for human UGT2B10.	Trifluoperazine	0-15	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	68-75
20133892-0	2010	Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine.	Nitrogen	25-26	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	14-21
20876810-3	2010	In the present study, the relationship between the levels of urinary nicotine metabolites and functional polymorphisms in UGTs 2B10 and 2B17 was analyzed in urine specimens from 104 Caucasian smokers.	Nicotine	69-77	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	122-140
20876810-6	2010	These data suggest that UGTs 2B10 and 2B17 play important roles in the glucuronidation of nicotine, cotinine, and 3HC and suggest that the UGT2B10 codon 67 SNP and the UGT2B17 gene deletion significantly reduce overall glucuronidation rates of nicotine and its major metabolites in smokers.	Nicotine	90-98	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-42
20876810-6	2010	These data suggest that UGTs 2B10 and 2B17 play important roles in the glucuronidation of nicotine, cotinine, and 3HC and suggest that the UGT2B10 codon 67 SNP and the UGT2B17 gene deletion significantly reduce overall glucuronidation rates of nicotine and its major metabolites in smokers.	Nicotine	90-98	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	139-146
20876810-6	2010	These data suggest that UGTs 2B10 and 2B17 play important roles in the glucuronidation of nicotine, cotinine, and 3HC and suggest that the UGT2B10 codon 67 SNP and the UGT2B17 gene deletion significantly reduce overall glucuronidation rates of nicotine and its major metabolites in smokers.	Cotinine	100-108	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-42
20876810-6	2010	These data suggest that UGTs 2B10 and 2B17 play important roles in the glucuronidation of nicotine, cotinine, and 3HC and suggest that the UGT2B10 codon 67 SNP and the UGT2B17 gene deletion significantly reduce overall glucuronidation rates of nicotine and its major metabolites in smokers.	Nicotine	244-252	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-42
20876810-6	2010	These data suggest that UGTs 2B10 and 2B17 play important roles in the glucuronidation of nicotine, cotinine, and 3HC and suggest that the UGT2B10 codon 67 SNP and the UGT2B17 gene deletion significantly reduce overall glucuronidation rates of nicotine and its major metabolites in smokers.	Nicotine	244-252	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	139-146
20457141-3	2010	Surprisingly, UGT2B4 and UGT2B10 mRNA were found to be abundant in human liver suggesting an underestimated role of the liver in detoxification of their major substrates, bile acids and eicosanoids.	Bile Acids and Salts	171-181	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	25-32
20457141-3	2010	Surprisingly, UGT2B4 and UGT2B10 mRNA were found to be abundant in human liver suggesting an underestimated role of the liver in detoxification of their major substrates, bile acids and eicosanoids.	Eicosanoids	186-197	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	25-32
20133892-0	2010	Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine.	Amitriptyline	73-86	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	14-21
20133892-0	2010	Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine.	Imipramine	88-98	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	14-21
20133892-0	2010	Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine.	Clomipramine	100-112	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	14-21
20133892-0	2010	Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine.	Trimipramine	118-130	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	14-21
20133892-1	2010	The role of human UDP glucuronosyltransferase (UGT) 2B10 in the N-glucuronidation of a number of tricyclic antidepressants was investigated and compared with that of UGT1A4 in both the Sf9 expressed system and human liver microsomes.	Nitrogen	64-65	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	18-56
20133892-2	2010	The apparent K(m) (S(50)) values for the formation of quaternary N-glucuronides of amitriptyline, imipramine, clomipramine, and trimipramine were 2.60, 16.8, 14.4, and 11.2 microM in UGT2B10 and 448, 262, 112, and 258 microM in UGT1A4, respectively.	n-glucuronides	65-79	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	183-190
20133892-2	2010	The apparent K(m) (S(50)) values for the formation of quaternary N-glucuronides of amitriptyline, imipramine, clomipramine, and trimipramine were 2.60, 16.8, 14.4, and 11.2 microM in UGT2B10 and 448, 262, 112, and 258 microM in UGT1A4, respectively.	Amitriptyline	83-96	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	183-190
20133892-2	2010	The apparent K(m) (S(50)) values for the formation of quaternary N-glucuronides of amitriptyline, imipramine, clomipramine, and trimipramine were 2.60, 16.8, 14.4, and 11.2 microM in UGT2B10 and 448, 262, 112, and 258 microM in UGT1A4, respectively.	Imipramine	98-108	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	183-190
20133892-2	2010	The apparent K(m) (S(50)) values for the formation of quaternary N-glucuronides of amitriptyline, imipramine, clomipramine, and trimipramine were 2.60, 16.8, 14.4, and 11.2 microM in UGT2B10 and 448, 262, 112, and 258 microM in UGT1A4, respectively.	Clomipramine	110-122	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	183-190
20133892-2	2010	The apparent K(m) (S(50)) values for the formation of quaternary N-glucuronides of amitriptyline, imipramine, clomipramine, and trimipramine were 2.60, 16.8, 14.4, and 11.2 microM in UGT2B10 and 448, 262, 112, and 258 microM in UGT1A4, respectively.	Trimipramine	128-140	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	183-190
20133892-3	2010	The kinetics of amitriptyline and imipramine glucuronidation in human liver microsomes exhibited a biphasic character, where the high- and low-affinity components were in good agreement with our results in expressed UGT2B10 and UGT1A4, respectively.	Amitriptyline	16-29	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	216-223
20133892-3	2010	The kinetics of amitriptyline and imipramine glucuronidation in human liver microsomes exhibited a biphasic character, where the high- and low-affinity components were in good agreement with our results in expressed UGT2B10 and UGT1A4, respectively.	Imipramine	34-44	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	216-223
20133892-5	2010	The in vitro clearances (CL(int) or CL(max)) were comparable between UGT2B10 and UGT1A4 for glucuronidation of imipramine, clomipramine, and trimipramine, whereas CL(int) of amitriptyline glucuronidation by UGT2B10 was more than 10-fold higher than that by UGT1A4.	Imipramine	111-121	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	69-76
20133892-6	2010	Nicotine was found to selectively inhibit UGT2B10 but not UGT1A4 activity.	Nicotine	0-8	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	42-49
19487247-5	2009	The conserved N-terminal domain histidine of UGT1A1, UGT1A6, UGT1A9, and UGT2B7 was mutated to proline and leucine 34 of UGT2B10 was substituted with histidine, and the capacity of the wild-type and mutant proteins to glucuronidate 4MU, 1NP, LTG, TFP, and naproxen was characterized.	glucuronidate	218-231	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	121-128
19786624-0	2010	Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype.	Nicotine	0-8	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	111-118
19786624-5	2010	In a second study of smokers (n = 84), the relationship of a UGT2B10 haplotype linked with D67Y to nicotine and cotinine glucuronidation levels was determined.	Nicotine	99-107	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	61-68
19786624-8	2010	In smokers with a UGT2B10 Tyr67 allele, glucuronide conjugation of nicotine and cotinine was decreased by 20% compared with smokers without this allele.	Glucuronides	40-51	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	18-25
19786624-8	2010	In smokers with a UGT2B10 Tyr67 allele, glucuronide conjugation of nicotine and cotinine was decreased by 20% compared with smokers without this allele.	Nicotine	67-75	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	18-25
19786624-8	2010	In smokers with a UGT2B10 Tyr67 allele, glucuronide conjugation of nicotine and cotinine was decreased by 20% compared with smokers without this allele.	Cotinine	80-88	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	18-25
19487247-1	2009	An N-terminal domain histidine [corresponding to position 39 of UDP-glucuronosyltransferase (UGT) 1A1] is conserved in all UGT1A and UGT2B subfamily proteins except UGT1A4 (Pro-40) and UGT2B10 (Leu-34).	Histidine	21-30	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	185-192
19487247-2	2009	Unlike most UGT1A and UGT2B xenobiotic-metabolizing enzymes, UGT1A4 and UGT2B10 lack the ability to glucuronidate 4-methylumbelliferone (4MU) and 1-naphthol (1NP), both planar phenols, and naproxen (a carboxylic acid).	Hymecromone	114-135	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	72-79
19487247-2	2009	Unlike most UGT1A and UGT2B xenobiotic-metabolizing enzymes, UGT1A4 and UGT2B10 lack the ability to glucuronidate 4-methylumbelliferone (4MU) and 1-naphthol (1NP), both planar phenols, and naproxen (a carboxylic acid).	Hymecromone	137-140	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	72-79
19487247-2	2009	Unlike most UGT1A and UGT2B xenobiotic-metabolizing enzymes, UGT1A4 and UGT2B10 lack the ability to glucuronidate 4-methylumbelliferone (4MU) and 1-naphthol (1NP), both planar phenols, and naproxen (a carboxylic acid).	1-naphthol	146-156	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	72-79
19487247-2	2009	Unlike most UGT1A and UGT2B xenobiotic-metabolizing enzymes, UGT1A4 and UGT2B10 lack the ability to glucuronidate 4-methylumbelliferone (4MU) and 1-naphthol (1NP), both planar phenols, and naproxen (a carboxylic acid).	1-naphthol	158-161	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	72-79
19487247-2	2009	Unlike most UGT1A and UGT2B xenobiotic-metabolizing enzymes, UGT1A4 and UGT2B10 lack the ability to glucuronidate 4-methylumbelliferone (4MU) and 1-naphthol (1NP), both planar phenols, and naproxen (a carboxylic acid).	Phenols	176-183	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	72-79
19487247-5	2009	The conserved N-terminal domain histidine of UGT1A1, UGT1A6, UGT1A9, and UGT2B7 was mutated to proline and leucine 34 of UGT2B10 was substituted with histidine, and the capacity of the wild-type and mutant proteins to glucuronidate 4MU, 1NP, LTG, TFP, and naproxen was characterized.	Naproxen	256-264	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	121-128
19487247-2	2009	Unlike most UGT1A and UGT2B xenobiotic-metabolizing enzymes, UGT1A4 and UGT2B10 lack the ability to glucuronidate 4-methylumbelliferone (4MU) and 1-naphthol (1NP), both planar phenols, and naproxen (a carboxylic acid).	Naproxen	189-197	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	72-79
19487247-2	2009	Unlike most UGT1A and UGT2B xenobiotic-metabolizing enzymes, UGT1A4 and UGT2B10 lack the ability to glucuronidate 4-methylumbelliferone (4MU) and 1-naphthol (1NP), both planar phenols, and naproxen (a carboxylic acid).	Carboxylic Acids	201-216	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	72-79
18474681-0	2008	Regio- and stereospecific N-glucuronidation of medetomidine: the differences between UDP glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes.	Nitrogen	26-27	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	127-134
19487247-5	2009	The conserved N-terminal domain histidine of UGT1A1, UGT1A6, UGT1A9, and UGT2B7 was mutated to proline and leucine 34 of UGT2B10 was substituted with histidine, and the capacity of the wild-type and mutant proteins to glucuronidate 4MU, 1NP, LTG, TFP, and naproxen was characterized.	Histidine	32-41	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	121-128
19487247-5	2009	The conserved N-terminal domain histidine of UGT1A1, UGT1A6, UGT1A9, and UGT2B7 was mutated to proline and leucine 34 of UGT2B10 was substituted with histidine, and the capacity of the wild-type and mutant proteins to glucuronidate 4MU, 1NP, LTG, TFP, and naproxen was characterized.	Proline	95-102	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	121-128
19487247-5	2009	The conserved N-terminal domain histidine of UGT1A1, UGT1A6, UGT1A9, and UGT2B7 was mutated to proline and leucine 34 of UGT2B10 was substituted with histidine, and the capacity of the wild-type and mutant proteins to glucuronidate 4MU, 1NP, LTG, TFP, and naproxen was characterized.	Leucine	107-114	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	121-128
19487247-5	2009	The conserved N-terminal domain histidine of UGT1A1, UGT1A6, UGT1A9, and UGT2B7 was mutated to proline and leucine 34 of UGT2B10 was substituted with histidine, and the capacity of the wild-type and mutant proteins to glucuronidate 4MU, 1NP, LTG, TFP, and naproxen was characterized.	Histidine	150-159	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	121-128
18502788-4	2008	However, H37 is not totally conserved, being replaced by either Pro or Leu in UGT1A4 and UGT2B10.	Leucine	71-74	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	89-96
18474681-0	2008	Regio- and stereospecific N-glucuronidation of medetomidine: the differences between UDP glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes.	Medetomidine	47-59	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	127-134
18300939-0	2008	Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines.	Nitrosamines	154-166	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	70-77
18238858-0	2008	Glucuronidation of tobacco-specific nitrosamines by UGT2B10.	Nitrosamines	36-48	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	52-59
18238858-8	2008	These data suggest that UGT2B10 is likely the most active UGT isoform in human liver for the N-glucuronidation of TSNAs.	Nitrogen	93-94	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
18300939-0	2008	Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines.	Nitrosamines	154-166	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	108-115
18300939-1	2008	OBJECTIVE: To study the potential association between UDP-glucuronosyltransferase (UGT)2B10 genotypes and [4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol] NNAL-N-glucuronidation activity in human liver microsomes (HLM) and to identify potential functional polymorphisms.	[4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol] nnal-n-glucuronidation	106-176	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	83-91
18300939-2	2008	METHODS: A total of 77 subjects were genotyped for three UGT2B10 tagging single nucleotide polymorphisms NNAL-N-glucuronidation activity in HLM was determined by high-pressure liquid chromatography and analyzed by UGT2B10 haplotypes.	nnal-n	105-111	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	57-64
18300939-6	2008	A novel polymorphism resulting in an aspartic acid to tyrosine amino acid change at codon 67 of the UGT2B10 complementary DNA was identified exclusively in subjects with a haplotype C. Unlike the high activity observed in microsomes from HEK293 cells over expressing the wild-type UGT2B10(67Asp) variant, microsomes from HEK293 cells over expressing the UGT2B10(67Tyr) variant exhibited minimal glucuronide formation activity against NNAL or other tobacco-specific nitrosamines tested in vitro.	Glucuronides	395-406	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	100-107
18300939-6	2008	A novel polymorphism resulting in an aspartic acid to tyrosine amino acid change at codon 67 of the UGT2B10 complementary DNA was identified exclusively in subjects with a haplotype C. Unlike the high activity observed in microsomes from HEK293 cells over expressing the wild-type UGT2B10(67Asp) variant, microsomes from HEK293 cells over expressing the UGT2B10(67Tyr) variant exhibited minimal glucuronide formation activity against NNAL or other tobacco-specific nitrosamines tested in vitro.	Nitrosamines	465-477	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	100-107
17909004-0	2007	Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism.	Nicotine	19-27	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	44-51
17909004-7	2007	These data suggest that UGT2B10 is the major hepatic enzyme involved in nicotine/cotinine glucuronidation and that the UGT2B10*2 variant significantly reduces nicotine- and cotinine-N-glucuronidation formation and plays an important role in nicotine metabolism and elimination.	Nitrogen	182-183	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	119-126
17909004-7	2007	These data suggest that UGT2B10 is the major hepatic enzyme involved in nicotine/cotinine glucuronidation and that the UGT2B10*2 variant significantly reduces nicotine- and cotinine-N-glucuronidation formation and plays an important role in nicotine metabolism and elimination.	Nicotine	159-167	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
17909004-7	2007	These data suggest that UGT2B10 is the major hepatic enzyme involved in nicotine/cotinine glucuronidation and that the UGT2B10*2 variant significantly reduces nicotine- and cotinine-N-glucuronidation formation and plays an important role in nicotine metabolism and elimination.	Nicotine	159-167	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	119-126
17909004-0	2007	Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism.	Nicotine	19-27	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	77-84
17909004-0	2007	Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism.	Cotinine	32-40	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	44-51
17909004-0	2007	Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism.	Aspartic Acid	95-98	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	77-84
17909004-0	2007	Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism.	Tyrosine	102-105	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	44-51
17909004-0	2007	Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism.	Tyrosine	102-105	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	77-84
17909004-2	2007	Recent studies have shown that UGT2B10 is a major enzyme involved in the N-glucuronidation of several tobacco-specific nitrosamines.	Nitrogen	73-74	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	31-38
17909004-2	2007	Recent studies have shown that UGT2B10 is a major enzyme involved in the N-glucuronidation of several tobacco-specific nitrosamines.	Nitrosamines	119-131	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	31-38
17909004-3	2007	In the present study, microsomes of UGT2B10-overexpressing HEK293 cells exhibited high N-glucuronidation activity against both nicotine and cotinine with apparent KM"s that were 37- and 3-fold lower than that observed for microsomes of UGT1A4-overexpressing cells against nicotine and cotinine, respectively.	Nitrogen	87-88	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	36-43
17909004-3	2007	In the present study, microsomes of UGT2B10-overexpressing HEK293 cells exhibited high N-glucuronidation activity against both nicotine and cotinine with apparent KM"s that were 37- and 3-fold lower than that observed for microsomes of UGT1A4-overexpressing cells against nicotine and cotinine, respectively.	Nicotine	127-135	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	36-43
17909004-3	2007	In the present study, microsomes of UGT2B10-overexpressing HEK293 cells exhibited high N-glucuronidation activity against both nicotine and cotinine with apparent KM"s that were 37- and 3-fold lower than that observed for microsomes of UGT1A4-overexpressing cells against nicotine and cotinine, respectively.	Cotinine	140-148	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	36-43
17909004-3	2007	In the present study, microsomes of UGT2B10-overexpressing HEK293 cells exhibited high N-glucuronidation activity against both nicotine and cotinine with apparent KM"s that were 37- and 3-fold lower than that observed for microsomes of UGT1A4-overexpressing cells against nicotine and cotinine, respectively.	Nicotine	272-280	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	36-43
17909004-3	2007	In the present study, microsomes of UGT2B10-overexpressing HEK293 cells exhibited high N-glucuronidation activity against both nicotine and cotinine with apparent KM"s that were 37- and 3-fold lower than that observed for microsomes of UGT1A4-overexpressing cells against nicotine and cotinine, respectively.	Cotinine	285-293	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	36-43
17909004-4	2007	The KM of microsomes from wild-type (WT) UGT2B10-overexpressing cells for nicotine and cotinine was similar to that observed for human liver microsomes (HLM) against both substrates.	Nicotine	74-82	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	41-48
17909004-4	2007	The KM of microsomes from wild-type (WT) UGT2B10-overexpressing cells for nicotine and cotinine was similar to that observed for human liver microsomes (HLM) against both substrates.	Cotinine	87-95	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	41-48
17909004-7	2007	These data suggest that UGT2B10 is the major hepatic enzyme involved in nicotine/cotinine glucuronidation and that the UGT2B10*2 variant significantly reduces nicotine- and cotinine-N-glucuronidation formation and plays an important role in nicotine metabolism and elimination.	Nicotine	72-80	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
17909004-7	2007	These data suggest that UGT2B10 is the major hepatic enzyme involved in nicotine/cotinine glucuronidation and that the UGT2B10*2 variant significantly reduces nicotine- and cotinine-N-glucuronidation formation and plays an important role in nicotine metabolism and elimination.	Nicotine	72-80	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	119-126
17909004-7	2007	These data suggest that UGT2B10 is the major hepatic enzyme involved in nicotine/cotinine glucuronidation and that the UGT2B10*2 variant significantly reduces nicotine- and cotinine-N-glucuronidation formation and plays an important role in nicotine metabolism and elimination.	Cotinine	81-89	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
17909004-7	2007	These data suggest that UGT2B10 is the major hepatic enzyme involved in nicotine/cotinine glucuronidation and that the UGT2B10*2 variant significantly reduces nicotine- and cotinine-N-glucuronidation formation and plays an important role in nicotine metabolism and elimination.	Cotinine	81-89	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	119-126
17909004-7	2007	These data suggest that UGT2B10 is the major hepatic enzyme involved in nicotine/cotinine glucuronidation and that the UGT2B10*2 variant significantly reduces nicotine- and cotinine-N-glucuronidation formation and plays an important role in nicotine metabolism and elimination.	Nicotine	159-167	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
17909004-7	2007	These data suggest that UGT2B10 is the major hepatic enzyme involved in nicotine/cotinine glucuronidation and that the UGT2B10*2 variant significantly reduces nicotine- and cotinine-N-glucuronidation formation and plays an important role in nicotine metabolism and elimination.	Nicotine	159-167	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	119-126
17909004-7	2007	These data suggest that UGT2B10 is the major hepatic enzyme involved in nicotine/cotinine glucuronidation and that the UGT2B10*2 variant significantly reduces nicotine- and cotinine-N-glucuronidation formation and plays an important role in nicotine metabolism and elimination.	Cotinine	173-181	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
17909004-7	2007	These data suggest that UGT2B10 is the major hepatic enzyme involved in nicotine/cotinine glucuronidation and that the UGT2B10*2 variant significantly reduces nicotine- and cotinine-N-glucuronidation formation and plays an important role in nicotine metabolism and elimination.	Cotinine	173-181	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	119-126
17909004-7	2007	These data suggest that UGT2B10 is the major hepatic enzyme involved in nicotine/cotinine glucuronidation and that the UGT2B10*2 variant significantly reduces nicotine- and cotinine-N-glucuronidation formation and plays an important role in nicotine metabolism and elimination.	Nitrogen	182-183	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	24-31
17576790-3	2007	The K(m) value of recombinant UGT2B10 for nicotine (0.29 mM) was similar to that determined for human liver microsomes (0.33 mM), whereas the K(m) value of UGT1A4 for nicotine was almost 10-fold greater (2.4 mM).	Nicotine	42-50	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	30-37
17576790-4	2007	UGT2B10 was also more active than UGT1A4 in N-glucuronidation of cotinine (oxidative nicotine metabolite), whereas UGT2B7 exhibited only low nicotine glucuronidation activity and was essentially inactive toward cotinine.	Nitrogen	44-45	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	0-7
17576790-2	2007	Using an improved analytical method, we have discovered that the human UDP-glucuronosyltransferase (UGT) 2B10, a liver enzyme previously unknown to conjugate nicotine or exhibit considerable activity toward any compound, plays a major role in nicotine inactivation by direct conjugation with glucuronic acid at the aromatic nitrogen atom.	Nicotine	158-166	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	71-109
17576790-2	2007	Using an improved analytical method, we have discovered that the human UDP-glucuronosyltransferase (UGT) 2B10, a liver enzyme previously unknown to conjugate nicotine or exhibit considerable activity toward any compound, plays a major role in nicotine inactivation by direct conjugation with glucuronic acid at the aromatic nitrogen atom.	Nicotine	243-251	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	71-109
17576790-2	2007	Using an improved analytical method, we have discovered that the human UDP-glucuronosyltransferase (UGT) 2B10, a liver enzyme previously unknown to conjugate nicotine or exhibit considerable activity toward any compound, plays a major role in nicotine inactivation by direct conjugation with glucuronic acid at the aromatic nitrogen atom.	Glucuronic Acid	292-307	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	71-109
17576790-2	2007	Using an improved analytical method, we have discovered that the human UDP-glucuronosyltransferase (UGT) 2B10, a liver enzyme previously unknown to conjugate nicotine or exhibit considerable activity toward any compound, plays a major role in nicotine inactivation by direct conjugation with glucuronic acid at the aromatic nitrogen atom.	Nitrogen	324-332	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	71-109
17576790-4	2007	UGT2B10 was also more active than UGT1A4 in N-glucuronidation of cotinine (oxidative nicotine metabolite), whereas UGT2B7 exhibited only low nicotine glucuronidation activity and was essentially inactive toward cotinine.	Cotinine	65-73	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	0-7
17576790-4	2007	UGT2B10 was also more active than UGT1A4 in N-glucuronidation of cotinine (oxidative nicotine metabolite), whereas UGT2B7 exhibited only low nicotine glucuronidation activity and was essentially inactive toward cotinine.	Nicotine	85-93	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	0-7
17576790-4	2007	UGT2B10 was also more active than UGT1A4 in N-glucuronidation of cotinine (oxidative nicotine metabolite), whereas UGT2B7 exhibited only low nicotine glucuronidation activity and was essentially inactive toward cotinine.	Cotinine	211-219	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	0-7
17576790-7	2007	These findings for UGT2B10 (but not for UGT1A4 and UGT2B7) were mirrored by human tissue activities because nicotine and cotinine glucuronidation rates in intestine microsomes were less than 0.1% that of human liver microsomes.	Nicotine	108-116	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	19-26
17576790-7	2007	These findings for UGT2B10 (but not for UGT1A4 and UGT2B7) were mirrored by human tissue activities because nicotine and cotinine glucuronidation rates in intestine microsomes were less than 0.1% that of human liver microsomes.	Cotinine	121-129	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	19-26